Aceprometazine, a known phenothiazine derivative, is a medication that garners attention primarily for its sedative and antiemetic properties. Marketed under various trade names such as Neurolept,
Acepromazine, and
Promazine, it has carved out a niche in both human and veterinary medicine. Initially developed and researched by pharmaceutical institutions focused on psychiatric and neurological conditions, Aceprometazine belongs to the larger class of antipsychotic drugs. Its principal indications are as a sedative, anti-
nausea, and anti-
allergy medication. While it has been used less frequently in humans in recent years due to the development of newer drugs with more favorable side effect profiles, it remains a staple in veterinary practice to sedate and calm animals, particularly during surgical procedures or stressful situations. Current research continues to explore its efficacy and safety, ensuring that it remains a valuable tool in both medical and veterinary settings.
The mechanism of action of Aceprometazine is multifaceted, primarily involving the blockade of
dopamine receptors in the brain, particularly the D2 subtype. This action is central to its efficacy as an antipsychotic and sedative. By inhibiting dopamine, a neurotransmitter associated with
psychotic symptoms and hyperactivity, Aceprometazine diminishes the occurrence of
hallucinations,
delusions, and
agitation. Additionally, it exerts antihistamine effects by blocking
histamine H1 receptors, which accounts for its sedative and anti-
allergy properties. Furthermore, it has anticholinergic effects, reducing secretions and
muscular spasms, which can be particularly beneficial in pre-anesthetic protocols. The comprehensive blockade of these receptors aids in mitigating nausea and vomiting, making it an effective antiemetic.
Aceprometazine can be administered through various routes, depending on the intended use and the species being treated. In humans, oral tablets are the most common form, although intramuscular and intravenous injections are also employed in clinical settings when rapid onset of action is required. The onset of action generally occurs within 30 minutes to an hour following oral administration, while injections provide more immediate effects, often within 15 minutes. For veterinary use, the drug is frequently administered via injection to ensure precise dosing and rapid onset, which is crucial during surgical procedures or acute stress situations. The dosage and frequency of administration are tailored to the specific needs of the patient, considering factors such as age, weight, and overall health status.
Despite its therapeutic benefits, Aceprometazine is not without side effects. Common adverse reactions include
drowsiness,
dizziness,
dry mouth, and blurred vision, attributable to its anticholinergic properties. More severe side effects may involve
extrapyramidal symptoms such as
tremors,
rigidity, and bradykinesia, which are reminiscent of
Parkinsonian symptoms due to dopamine blockade.
Hypotension, or low blood pressure, is another potential side effect, particularly following intravenous administration.
Contraindications for Aceprometazine use include patients with a history of hypersensitivity to phenothiazines, those with severe cardiovascular disorders, and individuals with
narrow-angle glaucoma or
urinary retention. Caution is advised in patients with a history of
seizures, as the drug may lower the seizure threshold. Additionally, it is not recommended for use in pregnant or breastfeeding women unless absolutely necessary, due to potential risks to the fetus or infant.
The concurrent use of Aceprometazine with other medications can result in significant drug interactions. For instance, combining it with central nervous system depressants such as alcohol, benzodiazepines, or opioids can lead to
profound sedation and
respiratory depression. Antihypertensive drugs may have an additive effect with Aceprometazine, leading to an increased risk of hypotension. Additionally, its anticholinergic effects can be potentiated by other medications with similar properties, such as certain antihistamines and tricyclic antidepressants, potentially resulting in severe anticholinergic toxicity. The use of
monoamine oxidase inhibitors (MAOIs) in conjunction with Aceprometazine is contraindicated due to the risk of hypertensive crisis and
serotonin syndrome.
In conclusion, Aceprometazine is a versatile medication with a broad range of applications in both human and veterinary medicine. Its efficacy as a sedative, antiemetic, and antihistamine makes it a valuable tool in various clinical settings. However, its use must be carefully managed due to its potential side effects and significant drug interactions. Ongoing research aims to further elucidate its safety profile and expand its therapeutic applications, ensuring that it continues to be a reliable option for healthcare professionals and veterinarians.
How to obtain the latest development progress of all drugs?
In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!


